Iconovo signs agreement for development of inhaled oxytocin in ICOone for maternal health

Lund, December 21, 2020. Iconovo AB (publ) today announced that the company has signed a development agreement with Monash University for the development of inhaled oxytocin in ICOone®. The agreement verifies the suitability of ICOone for use with innovative pharmaceuticals. Monash University’s Institute of Pharmaceutical Sciences (MIPS) is leading the development project supported by a research agreement with Janssen Pharmaceutica N.V., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, and ongoing support from long term partner GSK.

US FDA Type III Drug Master File submitted for capsule inhaler ICOcap® from Iconovo

Iconovo announce that the capsule-based dry powder inhaler ICOcap® has been submitted to U.S. Food and Drug Administration (FDA) by partner Stevanato…

Nomination Committee appointed at Iconovo

At the Annual General Meeting of 8 May 2020, it was resolved that Iconovo shall have a Nomination Committee consisting of four members representing the four largest shareholders as of 30 September 2020.

Abbreviated interim report january-september 2020

Good progress in customer projects

Iconovo recruits for increased customer focus and delivery of customer projects

Iconovo announces two new recruitments to increase focus on customers’ needs and to deliver their projects in an effective and high-quality manner. With a growing project portfolio and many projects in a very active late phase, Iconovo has made appointments to two new positions that will contribute to an increased capacity for delivering new as well as existing projects.

CEO Johan Wäborg presents Iconovo at Erik Penser Bank’s Company Day 24 September 2020

Johan Wäborg, CEO at Iconovo, presented Iconovo at Erik Penser Bank’s Company Day 24 September where he gave the story of Iconovo covering the business model, products and how Iconovo will generate royalty income as the projects mature and gets launched into the market.

Abbreviated interim report

Breakthrough in Asia with a fourth royalty agreementKey figures in TSEK unless otherwise indicated Apr-Jun 2020Apr-Jun 2019Jan-Jun 2020Jan-Jun 2019Jan-Dec…

Iconovo awarded Top Drug Delivery Device company 2020 by Medtech Outlook

Iconovo has been recognized as a leading solution provider of drug delivery devices by Medtech Outlook when the magazine listed 10 companies that are at the forefront of providing drug delivery device solutions and impacting the industry. Iconovo is profiled in the MedTech Outlook special edition of Drug Delivery Devices.

First ICOres® patent in the United States

United States Patent and Trademark Office has announced the intention to grant a patent (Notice of Allowance) regarding Iconovo’s inhalation device, ICOres. Iconovo has previously granted patents in Sweden, Europe (EPO), Japan and China. The new patent covers the technology used in many of Iconovo’s projects like generic Symbicort©.

Iconovo guides regarding value of generic Seebri® and Ultibro® for ICOcap® formulations

Iconovo announced July 8th that a regional licensing agreement had been signed with BNC Korea regarding the development of two inhalation capsule formulations for generic Ultibro® and Seebri® for ICOcap®. The agreement gives BNC Korea exclusive rights in a territory consisting of Korea, Japan, China, Taiwan, Russia, the CIS Countries and the Southeast Asian Countries (including Turkey). The deal has a milestones value of EUR 550.000 whereof EUR 150.000 is to be paid as an access fee. Iconovo estimates that most of the value will be in future royalty payments and not milestones payments.